2022

Cook DR, Kang M, Martin TD, Galanko JA, Loeza GH, Trembath DG, Justilien V, Pickering KA, Vincent DF, Jarosch A, Jurmeister P, Waters AM, Hibshman PS, Campbell AD, Ford CA, Keku TO, Yeh JJ, Lee MS, Cox AD, Fields AP, Sandler RS, Sansom OJ, Sers C, Schaefer A, Der CJ. Aberrant Expression and Subcellular Localization of ECT2 Drives Colorectal Cancer Progression and Growth. Cancer Res. 2022 Jan 1;82(1):90-104. doi: 10.1158/0008-5472.CAN-20-4218. Epub 2021 Nov 4.

Stalnecker CA, Grover KR, Edwards AC, Coleman MF, Yang R, DeLiberty JM, Papke B, Goodwin CM, Pierobon M, Petricoin EF, Gautam P, Wennerberg K, Cox AD, Der CJ, Hursting SD, Bryant KL. Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. Cancer Res. 2022 Feb 15;82(4):586-598. doi: 10.1158/0008-5472.CAN-21-1443.

Javaid S, Schaefer A, Goodwin CM, Nguyen VV, Massey FL, Pierobon M, Gambrell-Sanders D, Waters AM, Lambert KN, Diehl JN, Hobbs GA, Wood KC, Petricoin EF, Der CJ, Cox AD. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma. Mol Cancer Ther. 2022 May 4;21(5):762-774. doi: 10.1158/1535-7163.MCT-21-0142.

Schaefer A, Der CJ. RHOA Takes the RHOad Less Traveled to Cancer. Trends Cancer. 2022 Aug;8(8):655-669. doi: 10.1016/j.trecan.2022.04.005. Epub 2022 May 12.

Huynh MV, Hobbs GA, Schaefer A, Pierobon M, Carey LM, Diehl JN, DeLiberty JM, Thurman RD, Cooke AR, Goodwin CM, Cook JH, Lin L, Waters AM, Rashid NU, Petricoin EF 3rd, Campbell SL, Haigis KM, Simeone DM, Lyssiotis CA, Cox AD, Der CJ. Functional and Biological Heterogeneity of KRASQ61 Mutations. Sci Signal. 2022 Aug 9;15(746):eabn2694. doi: 10.1126/scisignal.abn2694. Epub 2022 Aug 9.

Fennell EMJ, Aponte-Collazo LJ, Wynn JD, Drizyte-Miller K, Leung E, Greer YE, Graves PR, Iwanowicz AA, Ashamalla H, Holmuhamedov E, Lang H, Karanewsky DS, Der CJ, Houry WA, Lipkowitz S, Iwanowicz EJ, Graves LM. Characterization of TR-107, a Novel Chemical Activator of the Human Mitochondrial Protease ClpP. Pharmacol Res Perspect. 2022 Aug;10(4):e00993. doi: 10.1002/prp2.993.

Diehl JN, Hibshman PS, Ozkan-Dagliyan I, Goodwin CM, Howard SV, Cox AD, Der CJ. Targeting the ERK Mitogen-activated Protein Kinase Cascade for the Treatment of KRAS-mutant Pancreatic Cancer. Adv Cancer Res. 2022;153:101-130. doi: 10.1016/bs.acr.2021.07.008. Epub 2021 Sep 2.

Mucha B, Qie S, Bajpai S, Tarallo V, Diehl JN, Tedeschi F, Zhou G, Gao Z, Flashner S, Klein-Szanto AJ, Hibshoosh H, Masataka S, Chajewski OS, Majsterek I, Pytel D, Hatzoglou M, Der CJ, Nakagawa H, Bass AJ, Wong KK, Fuchs SY, Rustgi AK, Jankowsky E, Diehl JA. Tumor Suppressor Mediated Ubiquitylation of hnRNPK is a Barrier to Oncogenic Translation. Nat Commun. 2022 Nov 3;13(1):6614. doi: 10.1038/s41467-022-34402-6.

Hobbs GA, Der CJ. KRASG12R_ Independent Macropinocytosis in Pancreatic Cancer. Subcell Biochem. 2022;98:205-221. doi: 10.1007/978-3-030-94004-1_11.

2021

Klionsky DJ, Abdel-Aziz AK, Abdelfatah S, Abdellatif M, Abdoli A, Abel S, Abeliovich H, Abildgaard MH, Abudu YP, Acevedo-Arozena A, Adamopoulos IE, Adeli K, Adolph TE, Adornetto A, Aflaki E, Agam G, Agarwal A, Aggarwal BB, Agnello M, Agostinis P, Agrewala JN, Agrotis A, Aguilar PV, Ahmad ST, Ahmed ZM, Ahumada-Castro U, Aits S, Aizawa S, Akkoc Y, Akoumianaki T, Akpinar HA, Al-Abd AM, Al-Akra L, Al-Gharaibeh A, Alaoui-Jamali MA, Alberti S, Alcocer-Gómez E, Alessandri C, Ali M, Alim Al-Bari MA, Aliwaini S, Alizadeh J, Almacellas E, Almasan A, Alonso A, Alonso GD, Altan-Bonnet N, Altieri DC, Álvarez ÉMC, Alves S, Alves da Costa C, Alzaharna MM, Amadio M, Amantini C, Amaral C, Ambrosio S, Amer AO, Ammanathan V, An Z, Andersen SU, Andrabi SA, Andrade-Silva M, Andres AM, Angelini S, Ann D, Anozie UC, Ansari MY, Antas P, Antebi A, Antón Z, Anwar T, Apetoh L, Apostolova N, Araki T, Araki Y, Arasaki K, Araújo WL, Araya J, Arden C, Arévalo MA, Arguelles S, Arias E, Arikkath J, Arimoto H, Ariosa AR, Armstrong-James D, Arnauné-Pelloquin L, Aroca A, Arroyo DS, Arsov I, Artero R, Asaro DML, Aschner M, Ashrafizadeh M, Ashur-Fabian O, Atanasov AG, Au AK, Auberger P, Auner HW, Aurelian L, Autelli R… Guidelines for the use and interpretations of essays for monitoring autophagy (4th edition)1 . Autophagy. 2021 Jan;17(1):1-382. doi: 10.1080/15548627.2020.1797280. Epub 2021 Feb 8.PMID: 33634751

Waters AM, Der CJ. Validation of Isoform – and Mutation – Specific RAS Antibodies. Methods Mol Biol. 2021;2262:91-103. doi: 10.1007/978-1-0716-1190-6_5.PMID: 33977472

Klomp JE, Klomp JA, Der CJ. The ERK mitogen-activated protein kinase signaling network: The final frontier in RAS signal transduction. Biochem Soc Trans. 2021 Feb 26;49(1):253-267. doi: 10.1042/BST20200507.

Papke B, Azam SH, Feng AY, Gutierrez-Ford C, Huggins H, Pallan PS, Van Swearingen AED, Egli M, Cox AD, Der CJ, Pecot CV. Silencing of Oncogenic KRAS by Mutant-Selective Small Interfering RNA. ACS Pharmacol Transl Sci. 2021 Feb 4;4(2):703-712. doi: 10.1021/acsptsci.0c00165. eCollection 2021 Apr 9.

Nienhüser H, Kim W, Malagola E, Ruan T, Valenti G, Middelhoff M, Bass A, Der CJ, Hayakawa Y, Wang TC. Mist1+ gastric isthmus stem cells are regulated by Wnt5a and expand in response to injury and inflammation in mice. Gut. 2021 Apr;70(4):654-665. doi: 10.1136/gutjnl-2020-320742. Epub 2020 Jul 24.

Waters AM, Khatib TO, Papke B, Goodwin CM, Hobbs GA, Diehl JN, Yang R, Edwards AC, Walsh KH, Sulahian R, McFarland JM, Kapner KS, Gilbert TSK, Stalnecker CA, Javaid S, Barkovskaya A, Grover KR, Hibshman PS, Blake DR, Schaefer A, Nowak KM, Klomp JE, Hayes TK, Kassner M, Tang N, Tanaseichuk O, Chen K, Zhou Y, Kalkat M, Herring LE, Graves LM, Penn LZ, Yin HH, Aguirre AJ, Hahn WC, Cox AD, Der CJ. Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition. Cell Rep. 2021 Jun 29;35(13):109291. doi: 10.1016/j.celrep.2021.109291.PMID: 34192548 

Barkovskaya A, Goodwin CM, Seip K, Hilmarsdottir B, Pettersen S, Stalnecker C, Engebraaten O, Briem E, Der CJ, Moestue SA, Gudjonsson T, Maelandsmo GM, Prasmickaite L. Detection of phenotype-specific therapeutic vulnerabilities in breast cells using a CRISPR loss-of-function screen. Mol Oncol. 2021 Aug;15(8):2026-2045. doi: 10.1002/1878-0261.12951. Epub 2021 May 1.PMID: 33759347 

Pedone KH, González-Pérez V, Leopold LE, Rasmussen NR, Der CJ, Cox AD, Ahmed S, Reiner DJ. Engineering Threshold-based selection systems. G3 (Bethesda). 2021 Sep 6;11(9):jkab234. doi: 10.1093/g3journal/jkab234.PMID: 34544135

Diehl JN, Hibshman PS, Ozkan-Dagliyan I, Goodwin CM, Howard SV, Cox AD, Der CJ. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer. Adv Cancer Res. 2022;153:101-130. doi: 10.1016/bs.acr.2021.07.008. Epub 2021 Sep 2.PMID: 35101228

Cox AD, Der CJ. Filling the GAPs in understanding RAS. Science. 2021 Oct 8;374(6564):152-153. doi: 10.1126/science.abl3639. Epub 2021 Oct 7.PMID: 34618580 

Chang WH, Nguyen TT, Hsu CH, Bryant KL, Kim HJ, Ying H, Erickson JW, Der CJ, Cerione RA, Antonyak MA. KRAS-dependent cancer cells promote survival by producing exosomes enriched in survivin. Cancer Lett. 2021 Oct 1;517:66-77. doi: 10.1016/j.canlet.2021.05.031. Epub 2021 Jun 8.PMID: 34111513

Diehl JN, Klomp JE, Snare KR, Hibshman PS, Blake DR, Kaiser ZD, Gilbert TSK, Baldelli E, Pierobon M, Papke B, Yang R, Hodge RG, Rashid NU, Petricoin EF 3rd, Herring LE, Graves LM, Cox AD, Der CJ. The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS mutant pancreatic cancer. J Biol Chem. 2021 Nov;297(5):101335. doi: 10.1016/j.jbc.2021.101335. Epub 2021 Oct 22.PMID: 34688654

Klomp JE, Lee YS, Goodwin CM, Papke B, Klomp JA, Waters AM, Stalnecker CA, DeLiberty JM, Drizyte-Miller K, Yang R, Diehl JN, Yin HH, Pierobon M, Baldelli E, Ryan MB, Li S, Peterson J, Smith AR, Neal JT, McCormick AK, Kuo CJ, Counter CM, Petricoin EF 3rd, Cox AD, Bryant KL, Der CJ. CHK1 Protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment. Cell Rep. 2021 Nov 30;37(9):110060. doi: 10.1016/j.celrep.2021.110060.PMID: 34852220

–

2020

Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF 3rd, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ. Atypical KRASG12R  Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. Cancer Discov. 2020 Jan;10(1):104-123. doi: 10.1158/2159-8290.CD-19-1006. Epub 2019 Oct 24.PMID: 31649109

Zhang H, Schaefer A, Wang Y, Hodge RG, Blake DR, Diehl JN, Papageorge AG, Stachler MD, Liao J, Zhou J, Wu Z, Akarca FG, de Klerk LK, Derks S, Pierobon M, Hoadley KA, Wang TC, Church G, Wong KK, Petricoin EF, Cox AD, Lowy DR, Der CJ, Bass AJ. Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. Cancer Discov. 2020 Feb;10(2):288-305. doi: 10.1158/2159-8290.CD-19-0811. Epub 2019 Nov 26.PMID: 31771969 

Stalnecker CA, Der CJ. RAS Wanted Dead or Alive: Advances in Targeting RAS Mutant Cancers. Sci Signal. 2020 Mar 24;13(624):eaay6013. doi: 10.1126/scisignal.aay6013.

Li YC, Lytle NK, Gammon ST, Wang L, Hayes TK, Sutton MN, Bast RC Jr, Der CJ, Piwnica-Worms D, McCormick F, Wahl GM. Analysis in RAS Protein Interactions in Living Cells Reveals a Mechanism for pan-ARS Depletion by Membrane-targeted RAS Binders. Proc Natl Acad Sci U S A. 2020 Jun 2;117(22):12121-12130. doi: 10.1073/pnas.2000848117. Epub 2020 May 18.

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Author Correction: Combination of ERK and Authophagy Inhibition as a Treatment Approach for Pancreatic Cancer. Nat Med. 2020 Jun;26(6):982. doi: 10.1038/s41591-020-0947-8.PMID: 32483362

Hobbs GA, Der CJ. Binge Drinking: Micropinocytosis Promotes Tumorigenic Growth of RAS-Mutant Cancers. Trends Biochem Sci. 2020 Jun;45(6):459-461. doi: 10.1016/j.tibs.2020.02.009. Epub 2020 Mar 9.PMID: 32413322

Ozkan-Dagliyan I, Diehl JN, George SD, Schaefer A, Papke B, Klotz-Noack K, Waters AM, Goodwin CM, Gautam P, Pierobon M, Peng S, Gilbert TSK, Lin KH, Dagliyan O, Wennerberg K, Petricoin EF 3rd, Tran NL, Bhagwat SV, Tiu RV, Peng SB, Herring LE, Graves LM, Sers C, Wood KC, Cox AD, Der CJ. Lowe-Dove Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. Cell Rep. 2020 Jun 16;31(11):107764. doi: 10.1016/j.celrep.2020.107764.PMID: 32553168 

Tew BY, Durand JK, Bryant KL, Hayes TK, Peng S, Tran NL, Gooden GC, Buckley DN, Der CJ, Baldwin AS, Salhia B. Genome-Wide DNA Methylation Analysis of KRAS Mutant Cell Lines. Sci Rep. 2020 Jun 23;10(1):10149. doi: 10.1038/s41598-020-66797-x.PMID: 32576853 

Hodge RG, Schaefer A, Howard SV, Der CJ. RAS and RHO Family GTPase mutations in Cancer: Twin Sons of Different Mothers? Crit Rev Biochem Mol Biol. 2020 Aug;55(4):386-407. doi: 10.1080/10409238.2020.1810622. Epub 2020 Aug 25.PMID: 32838579

Escobar-Hoyos LF, Penson A, Kannan R, Cho H, Pan CH, Singh RK, Apken LH, Hobbs GA, Luo R, Lecomte N, Babu S, Pan FC, Alonso-Curbelo D, Morris JP 4th, Askan G, Grbovic-Huezo O, Ogrodowski P, Bermeo J, Saglimbeni J, Cruz CD, Ho YJ, Lawrence SA, Melchor JP, Goda GA, Bai K, Pastore A, Hogg SJ, Raghavan S, Bailey P, Chang DK, Biankin A, Shroyer KR, Wolpin BM, Aguirre AJ, Ventura A, Taylor B, Der CJ, Dominguez D, Kümmel D, Oeckinghaus A, Lowe SW, Bradley RK, Abdel-Wahab O, Leach SD. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Cancer Cell. 2020 Aug 10;38(2):198-211.e8. doi: 10.1016/j.ccell.2020.05.010. Epub 2020 Jun 18.PMID: 32559497